Latest Headlines

Latest Headlines

Agilent buys Seahorse Bio for $235M to increase presence in research labs

Agilent continued its foray into diagnostics and scientific research equipment with the planned acquisition of Seahorse Bio for $235 million in cash. The deal is expected to close by Nov. 1.

Qualcomm buys medical device connectivity player Capsule Tech

Qualcomm Life is reaching further into healthcare and the hospital with its purchase of Capsule Technologie, thereby extending its existing focus on at-home healthcare products.

Perrigo racks up more opposition to Mylan's now-official hostile bid

It's official: Mylan has taken its Perrigo buyout offer to the Irish company's shareholders. But plenty of industry-watchers are still opposed to the idea.

Cantel to buy endoscope cleanliness startup for $80M

Infection prevention and control player Cantel Medical will purchase U.K. startup Medical Innovations Group for $79.5 million in cash. The acquisition adds a recently launched endoscope storage system as well as single-use endoscopy consumables, mobile cart systems and patient transport products.

Shire casts about for creative ways to woo Baxalta shareholders

After some serious pushback from Baxalta, Shire is weighing options when it comes to sweetening its $30.6 billion bid for the company. But it's not even sure how to go about doing it.

Nipro to buy partner, heart attack prediction imaging upstart Infraredx

Infraredx will be acquired by its Japanese partner and investor Nipro. The pair had an exclusive 5-year distribution deal in Japan for the company to sell the startup's cardiac imaging system. Nipro has already gained Japanese approval for the NIRS-IVUS True Vessel Characterization Imaging System from Infraredx to find cholesterol-rich, lipid core coronary plaques that are thought to precipitate heart attack.

UPDATED: ZS Pharma rockets up on word of a $2.5B offer from Actelion

ZS Pharma, awaiting FDA approval for a kidney drug, saw its share value soar about 30% after Actelion confirmed that it's discussing a multibillion-dollar buyout with the company.

Horizon steps up its official Depomed pursuit with campaign website

Horizon Pharma has officially begun mailing solicitation materials to shareholders of unwilling M&A target Depomed, including a letter related to its efforts to call the two special meetings it'll need if it wants to seal its deal.

Just wait, Perrigo investor urges. We can get the same return--without a Mylan deal

All eyes are on Perrigo's investors, who will have to decide whether to accept Mylan's offer when the wannabe acquirer takes it to them next Monday. And Israeli businessman Mori Arkin, for one, plans to deliver a resounding "no."

Gilead banks $10B, stirring fresh buzz about a blockbuster buyout

When Gilead laid out the terms for raising $10 billion yesterday, on top of the blockbuster money it earns on HIV and its hepatitis C drugs acquired in its buyout of Pharmasset, the move immediately stirred fresh buzz about what Gilead was going to buy next, and for how much.